Jannik Stemler, Sibylle C Mellinghoff, Yascha Khodamoradi, Rosanne Sprute, Annika Y Classen, Sonja E Zapke, Martin Hoenigl, Robert Krause, Martin Schmidt-Hieber, Werner J Heinz, Michael Klein, Philipp Koehler, Blasius Liss, Michael Koldehoff, Christoph Buhl, Olaf Penack, Georg Maschmeyer, Enrico Schalk, Cornelia Lass-Flörl, Meinolf Karthaus, Markus Ruhnke, Oliver A Cornely, Daniel Teschner
Patients with haematological malignancies (HM) are at high risk of developing invasive fungal disease (IFD) with high morbidity and attributable mortality. We reviewed data published until September 2021 to update the 2017 antifungal prophylaxis recommendations of the German Society of Haematology and Medical Oncology (DGHO). The strong recommendation to administer antifungal prophylaxis in patients with HM with long-lasting neutropenia, i.e. <500 cells/μL for >7 days remains unchanged. Posaconazole remains the drug of choice for mould-active prophylaxis in these patients...
August 2, 2023: Journal of Antimicrobial Chemotherapy